Approval · Notice of Compliance 33181 · 2024
M-AZITHROMYCIN: Notice of Compliance 33181
Issued May 6, 2024
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 33181
- Date
- May 6, 2024
- Company
- Mantra Pharma Inc.Brossard, Quebec, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to an Abbreviated New Drug Submission (SANDS), supplement
- Submission class
- Admin
- Reason
- Administrative: Labelling Update (to match Licensor)
- Canadian reference product
- ZITHROMAX (Pfizer Canada Ulc)
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| M-AZITHROMYCIN | Not yet assigned | — |
Medicinal ingredients
- AZITHROMYCIN DIHYDRATE 250 MG per TAB
- AZITHROMYCIN DIHYDRATE 600 MG per TAB